Recurrent Implantation Failure (RIF) — Investigation and Management

Recurrent implantation failure — failed pregnancy despite multiple good-quality embryo transfers — requires systematic investigation and tailored management. This page covers the modern approach to RIF.

1. Defining RIF

Contemporary definition: failed implantation despite transfer of 3 or more good-quality embryos (cleavage stage) or 2 or more good-quality blastocysts in patient under 40 with normal uterine anatomy. Older definitions varied. RIF is a working diagnosis triggering systematic investigation, not a final diagnosis.

2. Embryo factors

Even good morphology embryos may be aneuploid (chromosomally abnormal). Higher aneuploidy rates with advancing maternal age. PGT-A may identify implantation failure due to aneuploidy. Mosaic embryos. Embryo quality may be optimised by laboratory factors (time-lapse, vitrification protocols, transfer technique).

3. Uterine receptivity factors

Endometrial Receptivity Array (ERA) — identifies displaced window of implantation in ~25% of RIF cases. Adjusted timing transfer (pERA) in identified displacement. Endometrial volume, vascularity assessment. Endometrial scratch (debated evidence). Hysteroscopy for cavity assessment.

4. Chronic endometritis

Identified in 15–30 percent of RIF cases. Plasma cells (CD138) on endometrial biopsy. Often asymptomatic. Treatable with targeted antibiotics. Should be excluded in RIF investigation. Hysteroscopy with biopsy gold standard for diagnosis.

5. Anatomic factors

Hysteroscopy assessment — uterine septum, fibroids (intramural >4cm or submucous), polyps, adhesions, Müllerian anomalies. Saline-infusion sonography. Correction of identified anatomic factors. Hydrosalpinx (toxic to embryos) — surgical management.

6. Immune and thrombotic factors

Antiphospholipid antibodies — confirmed positive on two occasions, treated with aspirin + heparin in pregnancy. Inherited thrombophilias (Factor V Leiden, prothrombin) — testing in selected cases. Immunomodulator therapies (intralipids, IVIG, steroids) — evidence weak, used selectively. Reproductive immunology remains controversial.

7. Male factor in RIF

Sperm DNA fragmentation testing in RIF patients. May reveal undetected paternal contribution. ICSI with morphology selection (IMSI) or hyaluronic acid binding (PICSI). Lifestyle modification of male partner. Surgical sperm retrieval in extreme cases for testicular sperm.

8. RIF management approach

Systematic workup, not random interventions. PGT-A to address embryo factor. Hysteroscopy and CD138 biopsy for endometrial factors. ERA in selected cases. Sperm DNA fragmentation testing. Address identified factors. Empirical add-ons (immune therapies, scratch) with caution — limited evidence. Many RIF cases find correctable cause; some remain unexplained.

Frequently Asked Questions

Dr. Priyadatt Patel

Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead

MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation

ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.